Publications

Detailed Information

Comparative analysis of protein expressions in primary and metastatic gastric Carcinomas

DC Field Value Language
dc.contributor.authorKim, Ji Hun-
dc.contributor.authorKim, Min A.-
dc.contributor.authorLee, Hye Seung-
dc.contributor.authorKim, Woo Ho-
dc.date.accessioned2012-06-04T01:47:41Z-
dc.date.available2012-06-04T01:47:41Z-
dc.date.issued2009-03-
dc.identifier.citationHUMAN PATHOLOGY; Vol.40 3; 314-322ko_KR
dc.identifier.issn0046-8177-
dc.identifier.urihttps://hdl.handle.net/10371/76751-
dc.description.abstractBecause metastatic cancers are derived from their primary counterparts, their molecular profiles could reasonably be expected to be similar to those of primary cancers. However, this expectation has been proven to be untrue in several human cancers. To explore protein expressional differences in primary and metastatic gastric carcinoma, we evaluated the expressions of 32 tumor-associated proteins in 250 pairs of primary and metastatic gastric carcinoma tissues by immunohistochemistry using tissue array slides. In metastatic gastric carcinomas, the expressions of epidermal growth factor receptor, c-erbB2, and trefoil factor 1(TFF-1) were higher and those of beta-catenin, E-cadherin, fragile histone triad gene (FHIT), glutathione S transferase-pi (GST-pi), kangai 1 (KAI1), and nuclear factor-kappa B (NF-kappa B) were lower than in primary gastric carcinomas. Furthermore, the expressions of beta-catenin, E-cadherin, KAI1, and NF-kappa B were associated with an advanced T and combined stage. In addition, the loss of E-cadherin expression during lymph node metastasis or E-cadherin immunonegativity in metastatic lesions and epidermal growth factor receptor expression in primary gastric carcinomas were independently associated with a poor prognosis by multivariate analysis. In conclusion, the expression of some tumor-associated proteins and their prognostic significance in metastatic gastric carcinomas differ from those in primary tumors. Consequently, analysis of both metastatic gastric carcinomas and their primary counterparts may be required to fully determine the molecular characteristics of node-positive gastric carcinoma. (c) 2009 Elsevier Inc. All rights reserved.ko_KR
dc.language.isoenko_KR
dc.publisherW B SAUNDERS CO-ELSEVIER INCko_KR
dc.subjectStomach neoplasmsko_KR
dc.subjectLymphatic metastasisko_KR
dc.subjectTissue array analysisko_KR
dc.subjectNeoplasm proteinsko_KR
dc.subjectImmunohistochemistryko_KR
dc.titleComparative analysis of protein expressions in primary and metastatic gastric Carcinomasko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김지헌-
dc.contributor.AlternativeAuthor김민아-
dc.contributor.AlternativeAuthor이혜승-
dc.contributor.AlternativeAuthor김우호-
dc.identifier.doi10.1016/j.humpath.2008.07.013-
dc.citation.journaltitleHUMAN PATHOLOGY-
dc.description.citedreferenceDupont VN, 2007, INT J CANCER, V121, P1036-
dc.description.citedreferenceGalizia G, 2007, WORLD J SURG, V31, P1458, DOI 10.1007/s00268-007-9016-4-
dc.description.citedreferenceInamura K, 2007, HUM PATHOL, V38, P702, DOI 10.1016/j.humpath.2006.11.019-
dc.description.citedreferenceVincan E, 2007, CELLS TISSUES ORGANS, V185, P20, DOI 10.1159/000101299-
dc.description.citedreferenceLIETO E, 2007, ANN SURG ONCOL, V15, P69-
dc.description.citedreferenceDragovich T, 2006, J CLIN ONCOL, V24, P4922, DOI 10.1200/JCO.2006.07.1316-
dc.description.citedreferenceMotoori M, 2006, EUR J CANCER, V42, P1897, DOI 10.1016/j.ejca.2006.04.007-
dc.description.citedreferenceItaliano A, 2006, ANN ONCOL, V17, P981, DOI 10.1093/annonc/mdl038-
dc.description.citedreferenceArnold D, 2006, ONCOLOGIST, V11, P602-
dc.description.citedreference*AM JOINT COMM CAN, 2006, AJCC CANC STAG MAN-
dc.description.citedreferenceYoshimura A, 2006, PATHOBIOLOGY, V73, P40, DOI 10.1159/000093090-
dc.description.citedreferenceQuan AL, 2005, INT J RADIAT ONCOL, V63, P695, DOI 10.1016/j.ijrobp.2005.03.051-
dc.description.citedreferenceZidan J, 2005, BRIT J CANCER, V93, P552, DOI 10.1038/sj.bjc.6602738-
dc.description.citedreferenceKim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452-
dc.description.citedreferenceGamboa-Dominguez A, 2004, MODERN PATHOL, V17, P579, DOI 10.1038/modpathol.3800085-
dc.description.citedreferenceOue N, 2004, CANCER RES, V64, P2397-
dc.description.citedreferenceHirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069-
dc.description.citedreferenceHynes RO, 2003, CELL, V113, P821-
dc.description.citedreferenceLee HS, 2003, J PATHOL, V200, P39, DOI 10.1002/path.1288-
dc.description.citedreferenceKim HS, 2003, ANTICANCER RES, V23, P2863-
dc.description.citedreferenceRamaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060-
dc.description.citedreferenceNicholson RI, 2001, EUR J CANCER, V37, pS9-
dc.description.citedreferenceEl-Rifai W, 2001, INT J CANCER, V92, P832-
dc.description.citedreferenceHippo Y, 2001, CANCER RES, V61, P889-
dc.description.citedreferenceShinohara T, 2001, CANCER RES, V61, P673-
dc.description.citedreferenceJackson P, 2000, CANCER LETT, V157, P169-
dc.description.citedreferenceCano A, 2000, NAT CELL BIOL, V2, P76-
dc.description.citedreferenceBatlle E, 2000, NAT CELL BIOL, V2, P84-
dc.description.citedreferenceKakeji Y, 1999, ONCOL REP, V6, P1213-
dc.description.citedreferenceLe Beau MM, 1998, GENE CHROMOSOME CANC, V21, P281-
dc.description.citedreferenceSozzi G, 1996, CELL, V85, P17-
dc.description.citedreferenceTHEODORESCU D, 1991, INT J CANCER, V47, P118-
dc.description.citedreferencePARKIN DM, 1985, INT J CANCER, V54, P594-
dc.description.tc11-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share